Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II [a severe metabolic myopathy, Pompe disease (PD)] as the currently available therapy, replacement of the missing enzyme acid alpha-glucosidase, fails to reverse skeletal muscle pathology. PD, a paradigm for LSDs, is characterized by both lysosomal abnormality and dysfunctional autophagy. Here, we show that TFEB is a viable therapeutic target in PD: overexpression of TFEB in a new muscle cell culture system and in mouse models of the disease reduced glycogen load and lysosomal size, improved autophagosome processing, and alleviated excessive accumulation of autophagic vacuoles. Unexpectedly, the exocytosed vesicles were labelled with lysosomal and autophagosomal membrane markers, suggesting that TFEB induces exocytosis of autophagolysosomes. Furthermore, the effects of TFEB were almost abrogated in the setting of genetically suppressed autophagy, supporting the role of autophagy in TFEB-mediated cellular clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“strategies based on the enhancement of cellular waste disposal capacity (i.e., TFEB‐TFE3 gene therapy) hold promise of preclinical benefits in these pathological scenarios (Spampanato et al, 2013; Bajaj et al, 2019).”
From Autophagy in major human diseases (2021) · cites this paper as Spampanato et al, 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605 · cited 2×
“…abnormality in PD muscle fibres – autophagic accumulation (Raben et al, 2012) – was not reproduced in PD myotubes, as demonstrated by immunostaining and western analysis with LC3 [a highly specific autophagosomal marker (Kabeya et al, 2000)] (shown for western blot in Supporting Information Fig S1C).”
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
TFEB Links Autophagy to Lysosomal Biogenesis
Settembre, C., Di Malta, C., Polito, V. A., Arencibia, M. G., Vetrini, F., Erdin, S., Erdin, S. U., Huynh, T., Medina, D., Colella, P., et al. (2011) · Science · doi:10.1126/science.1204592 · Cited by 3,365 · cited 5×
“Furthermore, since TFEB has been shown to promote lysosomal– autophagosomal fusion (Settembre & Ballabio, 2011; Settembre et al, 2011), this approach, unlike most current efforts, has the potential to prevent or resolve autophagic build-up.”
InfluentialSelf-citationA Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543 · cited 5×
“Plasmids: plasmid containing the full-length 3xFlag-tagged human TFEB (referred to as Flag-TFEB) was described previously (Sardiello et al, 2009); plasmid containing the full-length rat LAMP1 (mCherry-LAMP1) was obtained from Dr. Kristien Zaal (Light Imaging Section, Office of Science & Technology,…”
InfluentialSelf-citationMammalian autophagy: core molecular machinery and signaling regulation
Yang, Z., & Klionsky, D. J. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.014 · Cited by 1,956 · cited 1×
“Defects in autophagy, a major lysosome-dependent degradative system (Yang & Klionsky, 2010)], significantly contribute to the pathophysiology of several lysosomal storage diseases (Cao et al, 2006; Cox & Cachon-Gonzalez, 2012; Fukuda et al, 2006a,b; Liao et al, 2007; Lieberman et al, 2012; Settembre…”
A lysosome‐to‐nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
Settembre, C., Zoncu, R., Medina, D. L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, G., Vellard, M. C., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.32 · Cited by 1,920
Self-citationLysosomes: fusion and function
Luzio, J. P., Pryor, P. R., & Bright, N. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2217 · Cited by 1,740 · cited 1×
“Lysosomal function depends on the ability of lysosomal membranes to fuse with other vesicles’ membranes and with the plasma membrane (Luzio et al, 2007).”
Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function
Saftig, P., & Klumperman, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2745 · Cited by 1,648 · cited 1×
“LAMPs are considered to be of key importance for lysosomal movement, maturation of autophago-somes and lysosomal exocytosis (Saftig & Klumperman, 2009).”
Roczniak-Ferguson, A., Petit, C. S., Froehlich, F., Qian, S., Ky, J., Angarola, B., Walther, T. C., & Ferguson, S. M. (2012) · Science Signaling · doi:10.1126/scisignal.2002790 · Cited by 1,366
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB
Martina, J. A., Chen, Y., Gucek, M., & Puertollano, R. (2012) · Autophagy · doi:10.4161/auto.19653 · Cited by 1,333 · cited 6×
“Next, we attempted to activate endogenous TFEB by pharmacologically targeting mTORC1, which has been shown to negatively regulate TFEB (Martina et al, 2012; RoczniakFerguson et al, 2012; Settembre et al, 2012).”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 101–200 of 342
Lysosomal Stress Response (LSR): Physiological Importance and Pathological Relevance
Lakpa, K. L., Khan, N., Afghah, Z., Chen, X., & Geiger, J. D. (2021) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-09990-7 · Cited by 88
The post‐translational regulation of transcription factor EB (TFEB) in health and disease
Takla, M., Keshri, S., & Rubinsztein, D. C. (2023) · EMBO Reports · doi:10.15252/embr.202357574 · Cited by 86
“Indeed, overexpression of TFEB rescues the cytotoxicity arising from the accumulation of toxic lipid, mucopoly-saccharide, and glycogen aggregates in mouse models of MSD, mucopolysaccharidosis type IIIA, and Pompe disease, respectively (Spampanato et al , 2013).”
BackgroundTFEB Biology and Agonists at a Glance
Chen, M., Dai, Y., Liu, S., Fan, Y., Ding, Z., & Li, D. (2021) · Cells · doi:10.3390/cells10020333 · Cited by 88
Pi, H., Li, M., Tian, L., Yang, Z., Yu, Z., & Zhou, Z. (2017) · Scientific Reports · doi:10.1038/srep43466 · Cited by 86
“…of TFEB by AAV-TFEB, the master transcriptional activator of the autophagy-lysosomal system, is shown to be beneficial in rescuing Pompe disease mouse model, enhancing autophagy and lysosome biogenesis in the liver, and reducing accumulation of Alpha-1-anti-trypsin in the livers of PiZ mice 57,58 .”
Impaired autophagy: The collateral damage of lysosomal storage disorders
Myerowitz, R., Puertollano, R., & Raben, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103166 · Cited by 85
“As a proof-of-principle, a successful attempt to alleviate the burden of autophagy in the affected muscle was made by overexpression of TFEB in myofibres from GAA /- mice [70].”
BackgroundSelf-citationAutophagy modulation: a potential therapeutic approach in cardiac hypertrophy
Wang, X., & Cui, T. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00145.2017 · Cited by 81
“In cellular and animal models of LSDs, forced TFEB overexpression enhances overall autophagy and lysosomal function and reduces the severity of disease phenotypes (59, 81, 104, 105).”
BackgroundFeeney, E. J., Austin, S. L., Chien, Y., Mandel, H., Schoser, B. G. H., Prater, S. N., Hwu, W., Ralston, E., Kishnani, P. S., & Raben, N. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-2 · Cited by 81
“By analyzing biopsies, we have previously demonstrated that dysfunction of macroautophagy (often referred to as autophagy), a major intracellular lysosome-dependent degradation pathway [15,16], contributes significantly to the pathogenesis of the disease and interferes with delivery of the drug to the lysosomes [17-21…”
BackgroundSelf-citationWang, H., Wang, R., Carrera, I., Xu, S., & Lakshmana, M. K. (2016) · eneuro · doi:10.1523/eneuro.0042-16.2016 · Cited by 76
“Consistent with cell culture studies (Dehay et al., 2010; Spampanato et al., 2013; Kilpatrick et al., 2015), protein levels of both LAMP1 and cathepsin May/June 2016, 3(3) e0042-16.”
BackgroundAutophagy Defects in Skeletal Myopathies
Margeta, M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032618 · Cited by 78
“In agreement with this model, the overexpression of TFEB (a transcription factor that drives lysosome biogenesis) also decreases autophagic buildup and glycogen accumulation in Pompe disease muscle (115), suggesting that a late block in the autophagic flux can be attenuated by increasing the number of lysosomes that a…”
BackgroundAutophagy in the Regulation of Tissue Differentiation and Homeostasis
Perrotta, C., Cattaneo, M. G., Molteni, R., & Palma, C. D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602901 · Cited by 79
Advancements in AAV-mediated Gene Therapy for Pompe Disease
Salabarria, S., Nair, J., Clément, N., Smith, B. K., Raben, N., Fuller, D., Byrne, B., & Corti, M. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190426 · Cited by 54
“resulted in a significant reduction of lysosomal glyco234 gen burden, thus serving as a substrate reduction 235 therapy [70]; 2) overexpression of TFEB and TFE3 236 in GAA-deficient muscle cells and in muscle of KO 237 mice stimulated autophagosomal-lysosomal fusion 238 and exocytosis, reduced lysosomal size and glyco…”
BackgroundMethodSelf-citationMolecular regulation of autophagy and its implications for metabolic diseases
Ryter, S. W., Koo, J. K., & Choi, A. M. K. (2014) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000068 · Cited by 74
Yu, L., Zhang, X., Yang, Y., Li, D., Tang, K., Zhao, Z., He, W., Wang, C., Sahoo, N., Converso‐Baran, K., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2736 · Cited by 74
Beyond indigestion: emerging roles for lysosome-based signaling in human disease
Ferguson, S. M. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.04.014 · Cited by 65
Nuclear miR-30b-5p suppresses TFEB-mediated lysosomal biogenesis and autophagy
Guo, H., Pu, M., Tai, Y., Chen, Y., Lu, H., Qiao, J., Wang, G., Chen, J., Qi, X., Huang, R., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0602-4 · Cited by 68
“In addition, in Pompe disease (glycogen storage disease type II), overexpression of TFEB reduces glycogen load and the excessive accumulation of autophagy vacuoles [44].”
BackgroundUnderstanding macrophage diversity at the ontogenic and transcriptomic levels
Gautier, E. L., & Yvan‐Charvet, L. (2014) · Immunological Reviews · doi:10.1111/imr.12231 · Cited by 73
Pomegranate activates TFEB to promote autophagy-lysosomal fitness and mitophagy
Tan, S., Yu, C. Y., Sim, Z. W., Low, Z. S., Lee, B., See, F., Min, N., Gautam, A., Chu, J. J. H., Ng, K. W., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37400-1 · Cited by 63
The Cell Biology of Tau Secretion
Merezhko, M., Uronen, R.-L., & Huttunen, H. J. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.569818 · Cited by 56
Reciprocal Crosstalk Between Autophagic and Endocrine Signaling in Metabolic Homeostasis
Sinha, R. A., Singh, B. K., & Yen, P. M. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1103 · Cited by 67
“In this regard, induction of autophagic flux by increasing the activity of TFEB (transcriptional master regulator of autophagylysosomal genes) has shown promising beneficial effects (389).”
BackgroundLeng, Y., Li, X., Zheng, F., Liu, H., Wang, C., Wang, X., Liao, Y., Liu, J., Meng, K., Yu, J., et al. (2023) · Advanced Materials · doi:10.1002/adma.202211059 · Cited by 63
Manifestations of Age on Autophagy, Mitophagy and Lysosomes in Skeletal Muscle
Triolo, M., & Hood, D. A. (2021) · Cells · doi:10.3390/cells10051054 · Cited by 64
TFEB-mediated lysosomal exocytosis alleviates high-fat diet–induced lipotoxicity in the kidney
Nakamura, J., Yamamoto, T., Takabatake, Y., Namba‐Hamano, T., Minami, S., Takahashi, A., Matsuda, J., Sakai, S., Yonishi, H., Maeda, S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.162498 · Cited by 60
“In Fabry disease, an LSD, multilamellar inclusions within lysosomes are found predominantly in podocytes and distal tubules (43).”
BackgroundInfluentialSelf-citationTherapeutic Benefit of Autophagy Modulation in Pompe Disease
Lim, J., Sun, B., Puertollano, R., & Raben, N. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.025 · Cited by 63
“Isolation and culturing of single live fibers on Matrigel-coated plates were done as previously described.(101) The fibers were allowed to settle overnight and incubated with PLA2 (10 mg/mL) (Sigma, P9279) for 3 hr.”
MethodSelf-citationYAP plays a crucial role in the development of cardiomyopathy in lysosomal storage diseases
Ikeda, S., Nah, J., Shirakabe, A., Zhai, P., Oka, S., Sciarretta, S., Guan, K., Shimokawa, H., & Sadoshima, J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci143173 · Cited by 59
“A new therapeutic approach for hypertrophic cardiomyopathy caused by LSD Recent studies have suggested that activation of TFEB is a viable therapeutic option for LSDs, increasing autophagosome processing and consequently improving protein and organelle quality control mechanisms (32, 40).”
BackgroundA Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells
Yoshida, T., Awaya, T., Jonouchi, T., Kimura, R., Kimura, S., Era, T., Heike, T., & Sakurai, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-14063-y · Cited by 57
Progress and challenges of gene therapy for Pompe disease
Ronzitti, G., Collaud, F., Laforet, P., & Mingozzi, F. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.67 · Cited by 51
“In Gaa−/− mice, the administration of AAV vectors encoding for TFEB in muscle were shown to induce lysosomal exocytosis that was associated with improved muscle performance and delayed disease progression in the absence of reduction of glycogen content in skeletal muscle (130).”
BackgroundInfluentialGatto, F., Rossi, B., Tarallo, A., Polishchuk, E., Polishchuk, R., Carrella, A., Nusco, E., Alvino, F. G., Iacobellis, F., De Leonibus, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15352-2 · Cited by 49
Self-citationThe Transcription Factor EB Links Cellular Stress to the Immune Response .
Nabar, N. R., & Kehrl, J. H. (2017) · PubMed Central · Cited by 60
Perrone, L., Squillaro, T., Napolitano, F., Terracciano, C., Sampaolo, S., & Melone, M. A. B. (2019) · Nutrients · doi:10.3390/nu11081881 · Cited by 58
“Indeed, promising results have been obtained by over-expressing TFEB for 45 days in the GAA mice model [129].”
BackgroundMolecular Mechanisms of Lysosome and Nucleus Communication
Zhao, Q., Gao, S. M., & Wang, M. C. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.06.004 · Cited by 53
“Overexpression of TFEB/TFE3 stimulates lysosomal exocytosis and promotes the clearance of undigested materials in several cell models of LSDs [67, 128, 129].”
BackgroundInfluentialThe endolysosomal system in conventional and unconventional protein secretion
Néel, E., Chiritoiu-Butnaru, M., Fargues, W., Denus, M., Colladant, M., Filaquier, A., Stewart, S. E., Lehmann, S., Zurzolo, C., Rubinsztein, D. C., et al. (2024) · Journal of Cell Biology · doi:10.1083/jcb.202404152 · Cited by 50
Matthews, I., Birnbaum, A., Gromova, A., Huang, A. W., Liu, K., Liu, E. A., Coutinho, K., McGraw, M., Patterson, D. C., Banks, M. T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113436 · Cited by 51
Braun, F., Blomberg, L., Brodesser, S., Liebau, M. C., Schermer, B., Benzing, T. R., & Kurschat, C. E. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000077 · Cited by 51
Castets, P., Frank, S., Sinnreich, M., & Rüegg, M. A. (2016) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-160153 · Cited by 49
“Functional autophagy constituted a prerequisite for TFEB-mediated lysosome exocytosis therapy [216].”
BackgroundInfluentialRepurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
Soldati, C., López-Fabuel, I., Wanderlingh, L. G., Macia, M. G., Monfregola, J., Esposito, A., Napolitano, G., Guevara‐Ferrer, M., Rosato, A. S., Krogsaeter, E., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013742 · Cited by 49
“TFEB can promote clearance of pathological storage both in vitro and in vivo in various models of LSDs (Sardiello et al, 2009; Spampanato et al, 2013; Palmer, 2015; Kauss et al, 2020).”
BackgroundSelf-citationThree-dimensional tissue-engineered human skeletal muscle model of Pompe disease
Wang, J., Zhou, C. J., Khodabukus, A., Tran, S., Han, S.-O., Carlson, A. L., Madden, L. R., Kishnani, P. S., Koeberl, D. D., & Bursac, N. (2021) · Communications Biology · doi:10.1038/s42003-021-02059-4 · Cited by 48
Lysosomal β-glucuronidase regulates Lyme and rheumatoid arthritis severity
Bramwell, K. K. C., Ma, Y., Weis, J. H., Chen, X., Zachary, J. F., Teuscher, C., & Weis, J. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci72339 · Cited by 49
“Recent work has demonstrated that overexpression of the master regulatory transcription factor of the CLEAR network, TFEB, leads to successful clearance of glycogen from lysosomes in both in vitro and mouse models of Pompe disease (56).”
BackgroundLysosomal Storage Diseases-Regulating Neurodegeneration
Onyenwoke, R. U., & Brenman, J. E. (2015) · Journal of Experimental Neuroscience · doi:10.4137/jen.s25475 · Cited by 37
The Lysosome and Intracellular Signalling
Hesketh, G. G., Wartosch, L., Davis, L. J., Bright, N. A., & Luzio, J. P. (2018) · Progress in molecular and subcellular biology · doi:10.1007/978-3-319-96704-2_6 · Cited by 54
c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder
Contreras, P. S., Tapía, P., González-Hódar, L., Peluso, I., Soldati, C., Napolitano, G., Matarese, M., Heras, M. L., Valls, C., Martinez, A. N., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101691 · Cited by 48
Self-citationAutolysosomal exocytosis of lipids protect neurons from ferroptosis
Ralhan, I., Chang, J., Moulton, M. J., Goodman, L. D., Lee, N. Y. J., Plummer, G., Pasolli, H. A., Matthies, D., Bellen, H. J., & Ioannou, M. S. (2023) · Journal of Cell Biology · doi:10.1083/jcb.202207130 · Cited by 42
X-linked myopathy with excessive autophagy: a failure of self-eating
Dowling, J. J., Moore, S. A., Kalimo, H., & Minassian, B. A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1393-4 · Cited by 48
“Another exciting and potentially relevant observation is the discovery that TFEB overexpression can improve aspects of Pompe disease pathology [36].”
Recent advances in musculoskeletal local drug delivery
Zhang, S., Xing, M. M. Q., & Li, B. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.043 · Cited by 47
Giamogante, F., Barazzuol, L., Maiorca, F., Poggio, E., Esposito, A., Masato, A., Napolitano, G., Vagnoni, A., Calí, T., & Brini, M. (2024) · Nature Communications · doi:10.1038/s41467-024-46007-2 · Cited by 45
“…of transcription factor EB (TFEB), the master regulator of autophagy, lysosomal biogenesis, and in intracellular clearance pathways which has been widely proposed as therapeutic target in cellular and mouse models for lysosomal storage disorders 47 – 50 and neurodegenerative diseases 51 – 56 .”
Differential autophagic responses to nano-sized materials
Popp, L., & Segatori, L. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.08.016 · Cited by 44
Xu, J., Zhang, X., & Zhang, Z. (2020) · Chinese Medicine · doi:10.1186/s13020-020-00402-1 · Cited by 45
An update on the bridging factors connecting autophagy and Nrf2 antioxidant pathway
Ning, B., Hang, S., Zhang, W., Mao, C., & Li, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232241 · Cited by 45
Pompe disease: Shared and unshared features of lysosomal storage disorders
Lim, J., Kakhlon, O., Li, L., Myerowitz, R., & Raben, N. (2015) · Rare Diseases · doi:10.1080/21675511.2015.1068978 · Cited by 47
“We have shown that overexpression of TFEB or TFE3 in Pompe muscle alleviated autophagic buildup and cleared cells of excess glycogen.(15,24) Consistent with the role of these transcription factors in stimulating lysosomal biogenesis,(14,25) a striking reduction in the number of large lysosomes in treated Pompe muscle…”
BackgroundSelf-citationRegulation of the autophagy system during chronic contractile activity-induced muscle adaptations
Kim, Y., & Hood, D. A. (2017) · Physiological Reports · doi:10.14814/phy2.13307 · Cited by 40
“We also explored other lysosomal markers such as LAMP1 and Cathepsin D, both of which are also known to be regulated by TFEB (Spampanato et al. 2013; Vodicka et al. 2016).”
BackgroundWang, Y., Huang, H., Jin, Y., Shen, K., Chen, X., Xu, Z., Jin, B., & Pan, H. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110591 · Cited by 42
Neuromuscular Development and Disease: Learning From in vitro and in vivo Models
Fralish, Z., Lotz, E. M., Chavez, T., Khodabukus, A., & Bursac, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.764732 · Cited by 42
Mitochondrial breakdown in skeletal muscle and the emerging role of the lysosomes
Triolo, M., & Hood, D. A. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.004 · Cited by 39
Ermini, L., Farrell, A., Alahari, S., Ausman, J., Park, C., Sallais, J., Melland‐Smith, M., Porter, T. R., Edson, M., Nevo, O., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.652651 · Cited by 43
“Disruption of TFEB function characterizes several neurodegenerative storage disorders and pharmacological induction of endogenous TFEB has been reported to be beneficial in correcting the disease’s phenotype (Dehay and Bezard, 2011; Medina et al., 2011; Spampanato et al., 2013; Polito et al., 2014; Xiao et al., 2014;…”
BackgroundUrine-derived cells: a promising diagnostic tool in Fabry disease patients
Slaats, G. G. G., Braun, F., Hoehne, M., Frech, L. E., Blomberg, L., Benzing, T. R., Schermer, B., Rinschen, M. M., & Kurschat, C. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-29240-w · Cited by 39
Lysosomes at the Crossroads of Cell Metabolism, Cell Cycle, and Stemness
Nowosad, A., & Besson, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042290 · Cited by 40
“Overexpression of TFEB and TFE3 in GAAdeficient muscle cells prevents glycogen accumulation and reduces lysosomal content by inducing exocytosis of autophagic vesicles, which seems promising to treat lysosomal storage disorders [209,210].”
BackgroundTFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle
Sato, Y., Kobayashi, H., Higuchi, T., Shimada, Y., Ida, H., & Ohashi, T. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.54 · Cited by 42
Kobolák, J., Molnár, K., Varga, E., Bock, I., Jezsó, B., Téglási, A., Zhou, S., Giudice, M. L., Hoogeveen‐Westerveld, M., Pijnappel, W. W. M. P., et al. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.04.021 · Cited by 41
“scription factor EB (TFEB) reduced the storage material load and LAMP1 compartment in a muscle cell culture system and a mouse model of Pompe disease [58], in mouse models of MPS IIIA (Sanfilippo syndrome), and in a multiple sulfatase deficiency (MSD) model [59], which was in accordance with our TFEB immunolocalizatio…”
BackgroundResultBiomarkers in Glycogen Storage Diseases: An Update
Molares-Vila, A., Corbalán-Rivas, A., Carnero-Gregorio, M., González-Cespón, J. L., & Rodríguez‐Cerdeira, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094381 · Cited by 40
van Weering, J. R. T., & Scheper, W. (2019) · CNS Drugs · doi:10.1007/s40263-019-00643-1 · Cited by 38
“The removal of intracellular undegraded material is (partly) attributed to secretion of lysosomal content to the extracellular space [89, 91].”
BackgroundLang, M., Pramstaller, P. P., & Pichler, I. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00555-7 · Cited by 40
“In this syndrome, caused by alpha-Glucosidase (GAA) deficiency, TFEB overexpression alleviated disease markers in vitro and in vivo through the induction of exocytosis of autophagolysosomes [201].”
BackgroundGuo, X., Tang, P., Chen, L., Liu, P., Hou, C., Zhang, X., Liu, Y., Li, C., Li, X., & Li, R. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00228 · Cited by 39
“Moreover, osteopetrosis-associated transmembrane protein 1 (OSTM1), in cooperation with chloride channel 7 (CLCN7), is essential for regulating lysosomal pH and Aβ clearance (Lange et al., 2006; Majumdar et al., 2011; Spampanato et al., 2013).”
BackgroundWang, H., Karuppan, M. K. M., Devadoss, D., Nair, M., Chand, H. S., & Lakshmana, M. K. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.06.003 · Cited by 38
Zhu, Y., Shen, J., Li, Y., Wei, X., Chen, F., Zhong, M., Gu, Z., Xie, Y., Jin, W. H., Liu, Z., et al. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.02.045 · Cited by 36
Biphasic regulation of lysosomal exocytosis by oxidative stress
Ravi, S., Pena, K. A., Chu, C. T., & Kiselyov, K. I. (2016) · Cell Calcium · doi:10.1016/j.ceca.2016.08.002 · Cited by 38
“Upregulation of lysosomal exocytosis is proposed to underlie the therapeutic effect of TFEB overexpression in several disease models [25, 31, 33].”
BackgroundKobayashi, T., Tsutsui, H., Shimabukuro-Demoto, S., Yoshida-Sugitani, R., Karyu, H., Furuyama-Tanaka, K., Ohshima, D., Kato, N., Okamura, T., & Toyama‐Sorimachi, N. (2017) · International Immunology · doi:10.1093/intimm/dxx063 · Cited by 34
Beclin‐1‐mediated activation of autophagy improves proximal and distal urea cycle disorders
Soria, L. R., Gurung, S., Sabbata, G. D., Perocheau, D. P. B., Angelis, A. D., Bruno, G., Polishchuk, E., Paris, D., Cuomo, P., Motta, A., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202013158 · Cited by 34
Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease
Moriggi, M., Capitanio, D., Torretta, E., Barbacini, P., Bragato, C., Sartori, P., Moggio, M. G., Maggi, L., Mora, M., & Gelfi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062850 · Cited by 35
Genistein Activates Transcription Factor EB and Corrects Niemann–Pick C Phenotype
Argüello, G., Balboa, E., Tapía, P., Castro, J., Yañez, M. J., Mattar, P., Pulgar, R., & Zanlungo, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084220 · Cited by 36
Transition metals activate TFEB in overexpressing cells
Pena, K. A., & Kiselyov, K. I. (2015) · Biochemical Journal · doi:10.1042/bj20140645 · Cited by 35
Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology
Goina, E., Peruzzo, P., Bembi, B., Dardis, A., & Buratti, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.019 · Cited by 37
“At present, the only viable strategy that might be used, together with ERT, to improve its efficacy is the finding that overexpression of the TFEB transcription factor can lead to glycogen reduction in muscle cell cultures and mouse models of the disease.(35,36) Therefore, there is ample room for the search for additi…”
Enhanced Efficacy from Gene Therapy in Pompe Disease Using Coreceptor Blockade
Han, S.-O., Li, S., Brooks, E. D., Masat, E., Leborgne, C., Banugaria, S. G., Bird, A., Mingozzi, F., Waldmann, H., & Koeberl, D. D. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.115 · Cited by 33
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 37
The mucolipin-1 TRPML1 ion channel transmembrane-163 TMEM163 protein and lysosomal zinc handling
Kiselyov, K. I. (2017) · Frontiers in bioscience · doi:10.2741/4546 · Cited by 33
Biomedical Implications of Autophagy in Macromolecule Storage Disorders
Palhegyi, A. M., Seranova, E., Dimova, S., Hoque, S., & Sarkar, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00179 · Cited by 34
“Autophagy activation by itself, either genetically via TFEB or TFE3 overexpression or pharmacologically with rapamycin, reduced glycogen and autophagosome load by promoting autophagosome maturation and lysosomal exocytosis in the myotubes of GSDII mice and patients and in iPSCderived skeletal muscles (Ashe et al., 201…”
BackgroundYañez, M. J., Marín, T., Balboa, E., Klein, A. D., Alvarez, A. R., & Zanlungo, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165875 · Cited by 33
Mani, K. M., Javaheri, A., & Diwan, A. (2018) · Comprehensive physiology · doi:10.1002/cphy.c180005 · Cited by 31
Colella, P., Sellier, P., Gómez, M. J., Biferi, M. G., Tanniou, G., Guerchet, N., Cohen-Tannoudji, M., Moya‐Nilges, M., van Wittenberghe, L., Danièle, N., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103052 · Cited by 29
Yu, S., Wang, Z., Ding, L., & Yang, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117418 · Cited by 30
Connexin43 promotes exocytosis of damaged lysosomes through actin remodelling
Domingues, N., Catarino, S., Cristóvão, B., Rodrigues, L., Carvalho, F. A., Sarmento, M. J., Zuzarte, M., Almeida, J., Ribeiro-Rodrigues, T., Correia-Rodrigues, Â., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00177-3 · Cited by 28
“The accumulation of dysfunctional lysosomes with compromised membrane integrity has been implicated in various pathologies (Medina et al, 2011; Palmieri et al, 2017; Samie and Xu, 2014; Spampanato et al, 2013).”
BackgroundInnovative Treatments for Lysosomal Diseases
Cox, T. M. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.01.001 · Cited by 34
Nilsson, M. I., MacNeil, L., Kitaoka, Y., Suri, R. S., Young, S. P., Kaczor, J. J., Nates, N., Ansari, M. U., Wong, T. W. Y., Ahktar, M. A., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.019 · Cited by 30
Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases
Favret, J., Weinstock, N. I., Feltri, M. L., & Shin, D. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00057 · Cited by 31
“Recent attempts to increase autophagy in LSDs has been successfully employed in a variety of pre-clinical models including overexpression of the MiTF transcription factors TFEB and TFE3 (Spampanato et al., 2013; Rega et al., 2016) or by manipulation of the mTOR pathway (Bartolomeo et al., 2014).”
BackgroundLiang, Q., Catalano, F., Vlaar, E. C., Pijnenburg, J. M., Stok, M., van Helsdingen, Y., Vulto, A. G., van der Ploeg, A. T., van Til, N. P., & Pijnappel, W. W. M. P. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.010 · Cited by 29
Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease
Tarallo, A., Damiano, C., Strollo, S., Minopoli, N., Indrieri, A., Polishchuk, E., Zappa, F., Nusco, E., Fecarotta, S., Porto, C., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114434 · Cited by 29
Self-citationvon Kleist, L., Ariunbat, K., Braren, I., Stauber, T., Storch, S., & Danyukova, T. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.09.009 · Cited by 27
Impairment of homeostasis in lysosomal storage disorders
Segatori, L. (2014) · IUBMB Life · doi:10.1002/iub.1288 · Cited by 29
“Interestingly, the reduction of storage material was found to parallel TFEB-induced exocytosis of autophagolysosomes, supporting the notion that autophagy plays a critical role in TFEB-mediated clearance (47).”
BackgroundBullón, P., Castejón‐Vega, B., Román-Malo, L., Guerrero, M. J., Cotán, D., Forbes-Hernández, T. Y., Varela‐López, A., Pérez‐Pulido, A. J., Giampieri, F., Quiles, J. L., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.01.018 · Cited by 27
Nutrition and exercise in Pompe disease
Tarnopolsky, M. A., & Nilsson, M. I. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.52 · Cited by 29
“Interestingly, Raben’s group recently demonstrated that GAA KO mice exhibit an impairment in the mTOR signalling pathway with sequestration of mTORC1 to the lysosome due to a lysosomal acidification defect and constitutive excess of TSC2, which ultimately inhibits mTORC1 activity (despite being localized to the lysoso…”
BackgroundeIF4A3 regulates the TFEB-mediated transcriptional response via GSK3B to control autophagy
Sakellariou, D., Tiberti, M., Kleiber, T., Blázquez, L., López, A. R., Abildgaard, M. H., Lubas, M., Bártek, J., Papaleo, E., & Frankel, L. B. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00822-y · Cited by 28
Emerging role of mitophagy in myoblast differentiation and skeletal muscle remodeling
Rahman, F. A., & Quadrilatero, J. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.11.026 · Cited by 27
An, J. H., Hong, S.-E., Yu, S., Kang, J., Park, C. G., Lee, H. Y., Lee, S. K., Lee, D. C., Park, H., Hwang, W.-M., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01318-8 · Cited by 26
Basile, I., Silva, A. D., Cheikh, K. E., Godefroy, A., Daurat, M., Harmois, A., Perez, M., Caillaud, C., Charbonné, H.-V., Pau, B., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.043 · Cited by 26
“The abnormal autophagic pathways in Pompe mice were characterized in biopsies by clusters of densely packed late endosomes/lysosomes and autophagosomes [29,30].”
BackgroundFarah, B. L., Yen, P. M., & Koeberl, D. D. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.11.005 · Cited by 29
Agostini, F., Agostinis, R., Medina, D. L., Bisaglia, M., Greggio, E., & Plotegher, N. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02895-3 · Cited by 27
“While cells treated with the mTOR inhibitor Torin1, which induces a downstream activation of TFEB, failed to rescue the lysosomal phenotype in this model, the overexpression of TFEB in the same model was able to induce cellular clearance, suggesting that in these pathological conditions the amount of endogenous TFEB i…”
BackgroundFluoxetine ameliorates mucopolysaccharidosis type IIIA
Capuozzo, A., Montefusco, S., Cacace, V., Sofia, M., Esposito, A., Napolitano, G., Nusco, E., Polishchuk, E., Pizzo, M. T., Risi, M. D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.037 · Cited by 25
Iron-induced cytotoxicity mediated by endolysosomal TRPML1 channels is reverted by TFEB
Fernández, B., Olmedo, P., Gil, F., Fdez, E., Naaldijk, Y., Rivero-Ríos, P., Bracher, F., Grimm, C. M., Churchill, G. C., & Hilfiker, S. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05504-2 · Cited by 25
“Since TFEB overexpression is able to restore lysosomal morphology and function in various cellular and animal models of lysosomal storage diseases [15, 17, 61, 62], we wondered whether its expression may also rescue the endolysosomal iron overload-associated cytotoxicity.”
BackgroundRabinovich-Nikitin, I., & Kirshenbaum, L. A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146821 · Cited by 26
“A recent study showed that overexpression of TFEB in myotubes and muscle fibers in Pompe disease, a subtype of LSD, increased the formation and clearance of autophagolysosomes by enhancing lysosomal and cell-membrane fusion (5).”
BackgroundStępień, K. M., Cufflin, N., Donald, A., Jones, S. A., Church, H. J., & Hargreaves, I. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810573 · Cited by 23
“In vitro and in vivo overexpression of the transcription factor gene TFEB was found to enhance glycogen clearance and induce exocytosis, also resulting in some improvements in physical performance in the mouse model of Pompe disease [72,73].”
BackgroundMerlini, L., & Nishino, I. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.03.009 · Cited by 28
Chu, A. S., Perlmutter, D. H., & Wang, Y. (2014) · BioMed Research International · doi:10.1155/2014/459823 · Cited by 23
“These effects were blunted in autophagy-deficient cells [42].”
Background
Metadata
- Authors
- Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., Ballabio, A., & Raben, N.
- Affiliations
- Baylor College of Medicine (US)
- National Institutes of Health (US)
- Telethon Institute Of Genetics And Medicine (IT)
- Federico II University Hospital (IT)
- Corresponding author
- Ballabio, Andrea
- Raben, Nina
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-04-18
- Volume
- 5
- Issue
- 5
- Pages
- 691-706
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3662313
- OpenAlex
- W2113698463
- Cited by
- 341
- References
- 68
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 23 · 2023: 20 · 2022: 24 · 2021: 33 · 2020: 29 · 2019: 37 · 2018: 22 · 2017: 22 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 10
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- March of Dimes Foundation
- Beyond Batten Disease Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS078072)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- FP7 Ideas: European Research Council (250154)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- TFEB, Pompe disease, lysosomal storage disease, autophagy, lysosomal exocytosis, acid alpha-glucosidase deficiency, skeletal muscle, therapeutic target, lysosomal dysfunction
- MeSH terms
- Adenoviridae, alpha-Glucosidases, Animals, Autophagy, Cells, Cultured, Disease Models, Animal, Exocytosis, Genetic Vectors, Glycogen, Glycogen Storage Disease Type II, Lysosomes, Mice, Knockout, Muscle, Skeletal, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.